MELBOURNE, Australia--(BUSINESS WIRE)-- Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® (pronounced in-a-veer) in Japan. Inavir® is Daiichi Sankyo’s brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.
Inavir® (laninamivir octanoate), is the first drug of a new class of long acting neuraminidase inhibitors (LANIs) to address the limitation of the current products, which require daily or more frequent dosing. Neuraminidase inhibitors (NIs) are antiviral agents effective against influenza, providing both for the treatment of an established influenza infection or for the prevention of influenza prior to exposure. NIs are antiviral medicines and are not vaccines.
The new class of long acting neuraminidase inhibitors provide the opportunity to medicate patients on a “one and done” basis and offer a number of potential benefits. These include that the patient is more likely to use the product properly and as intended and also offers a reduced cost of storage and transport per course, where the product is intended to be stockpiled.
In 2003, Biota and Daiichi Sankyo merged their respective LANI programs. Under the co-ownership agreement, Daiichi Sankyo held an option to manufacture and sell laninamivir in Japan, in return for funding an extensive range of Japanese clinical trials. Under the agreement, Biota will receive a royalty on all sales in Japan and may also qualify for certain sale’s milestone payments.
Daiichi Sankyo and Biota have been in discussion with a number of suitable companies for the licensing of laninamivir in the rest of world. Those discussions are continuing. The Companies are confident that laninamivir will prove to be a valuable therapeutic product with many patient and community advantages.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients
in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group
is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit www.daiichisankyo.com
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.
Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
*Further information available at www.biota.com.au
Investor / Analyst Enquiries
Biota Holdings Limited
Peter Cook, +61 3 9915 3720
Damian Lismore, +61 3 9915 3721
Hinton & Associates
Jo Lynch, +61 3 9600 1979
+61 411 208 101 (mobile)
Blueprint Life Science Group
Remy Bernarda, +1-415-203-6386
KEYWORDS: Australia United States North America Australia/Oceania California
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Genetics Infectious Diseases Pharmaceutical Research Science